Get the Stockscreener App
86.71
1.40%
1.1348
Edwards Lifesciences Corp stock is traded at $86.71, with a volume of 1.11M.
It is up +1.40% in the last 24 hours and up +18.96% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$85.58
Open:
$85.08
24h Volume:
1.11M
Relative Volume:
0.25
Market Cap:
$50.88B
Revenue:
$5.88B
Net Income/Loss:
$1.34B
P/E Ratio:
36.92
EPS:
2.3489
Net Cash Flow:
$799.60M
1W Performance:
+5.26%
1M Performance:
+18.96%
6M Performance:
+14.94%
1Y Performance:
+30.46%
1-Day Range:
$84.94
$87.20
1-Week Range:
$82.01
$87.20
52-Week Range:
$65.31
$87.20
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
86.67 | 49.66B | 5.88B | 1.34B | 799.60M | 2.3489 |
|
ABT
Abbott Laboratories
|
128.59 | 224.00B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
104.85 | 154.37B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
373.61 | 140.48B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
96.08 | 122.89B | 34.20B | 4.69B | 5.30B | 3.6218 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Edwards Lifesciences stock hits 52-week high at 87.13 USD - Investing.com
Marble Harbor Investment Counsel LLC Trims Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Argus Research Adjusts Edwards Lifesciences Price Target to $105 From $90, Maintains Buy Rating - MarketScreener
Is Edwards Lifesciences Corporation (EWL) stock positioned for secular growthJuly 2025 Sector Moves & Verified Swing Trading Watchlists - newser.com
Will Edwards Lifesciences Corporation (EWL) stock test record highs in 2025Sell Signal & Accurate Technical Buy Alerts - newser.com
What is the fair value estimate for Edwards Lifesciences Corporation (EWL) stock in 20252025 AllTime Highs & Consistent Return Investment Signals - newser.com
What consensus target says about Edwards Lifesciences Corporation stockWeekly Investment Report & Expert Curated Trade Ideas - newser.com
Is Edwards Lifesciences Corporation (EWL) stock a safe buy pre earningsGold Moves & Verified Momentum Stock Alerts - newser.com
Published on: 2025-11-12 21:27:18 - newser.com
Can Edwards Lifesciences Corporation stock sustain institutional interestEarnings Summary Report & Breakout Confirmation Trade Signals - newser.com
Published on: 2025-11-12 18:17:35 - newser.com
How Edwards Lifesciences Corporation stock trades after rate cuts2025 Valuation Update & High Conviction Buy Zone Alerts - newser.com
Edwards Lifesciences Corporatio (EW) Stock Forecasts - Yahoo Finance
Shareholder Wood Files To Sell 26,850 Of Edwards Lifesciences Corp [EW] - TradingView
[144] Edwards Lifesciences Corp SEC Filing - Stock Titan
Using data models to predict Edwards Lifesciences Corporation stock movementSell Signal & Community Consensus Trade Alerts - newser.com
Edwards Lifesciences Corporation $EW Shares Purchased by Savant Capital LLC - MarketBeat
Will Edwards Lifesciences Corporation stock return to pre crash levelsWeekly Stock Summary & Short-Term Trading Opportunity Alerts - newser.com
Edwards Lifesciences (NYSE:EW) CFO Scott Ullem Sells 13,000 Shares - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Rathbones Group PLC Sells 499,459 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Stock: Is Wall Street Bullish or Bearish? - Barchart.com
Edwards Lifesciences Insider Sold Shares Worth $1,080,093, According to a Recent SEC Filing - MarketScreener
Acadian Asset Management LLC Buys 316,977 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW): Exploring Valuation as Earnings Upgrades and Guidance Fuel Options Market Volatility - Yahoo Finance
Edwards Lifesciences CFO Ullem sells $1m in shares By Investing.com - Investing.com Nigeria
Edwards Lifesciences CVP Lippis sells $84,196 in stock - Investing.com
Edwards Lifesciences CFO Ullem sells $1m in shares - Investing.com
Executives at Edwards Lifesciences Corp Execute Stock Sales - TradingView
CFO Ullem Sells 13,000 ($1.1M) Of Edwards Lifesciences Corp [EW] - TradingView
[Form 4] Edwards Lifesciences Corp Insider Trading Activity - Stock Titan
VP Lippis Files To Sell 3,058 Of Edwards Lifesciences Corp [EW] - TradingView
Aortic Innovations LLC v. Edwards Lifesciences Corp. (Fed. Cir. 2025) - JD Supra
Edwards backs AHA’s heart valve disease initiative - MassDevice
Edwards Lifesciences Corp (HAM:EWL) Stock Price, Trades & News - GuruFocus
Edwards Lifesciences (HAM:EWL) Inventories, Finished Goods : €547 Mil (As of Sep. 2025) - GuruFocus
Edwards Lifesciences (HAM:EWL) Earnings Yield (Joel Greenbl - GuruFocus
Edwards Lifesciences (HAM:EWL) Inventories, Raw Materials & Components : €190 Mil (As of Sep. 2025) - GuruFocus
Edwards Lifesciences (HAM:EWL) Price-to-Tangible-Book : 6.64 (As of Nov. 10, 2025) - GuruFocus
Edwards Lifesciences (HAM:EWL) YoY Rev. per Sh. Growth : 10.74% (As of Sep. 2025) - GuruFocus
Edwards Lifesciences (HAM:EWL) Cash Flow from Discontinued Operations : €0 Mil (TTM As of Sep. 2025) - GuruFocus
Edwards Lifesciences Corporation stock trend forecastPortfolio Return Report & Verified Chart Pattern Trade Signals - newser.com
Why Edwards Lifesciences Corporation stock attracts HNW investors2025 Price Targets & AI Enhanced Trading Signals - newser.com
Will Edwards Lifesciences Corporation stock outperform foreign stocksWeekly Trend Report & Low Risk High Win Rate Stock Picks - newser.com
Mitsubishi UFJ Asset Management Co. Ltd. Acquires 65,337 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Aviva PLC Trims Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
What does recent volatility data suggest for Edwards Lifesciences CorporationWeekly Trading Summary & AI Optimized Trade Strategies - newser.com
Edwards Lifesciences (HAM:EWL) ROC % : 16.48% (As of Sep. 2025) - GuruFocus
Edwards Lifesciences Corp Stock Warning Signs | HAM:EWL - GuruFocus
Edwards Lifesciences (HAM:EWL) Other Income (Minority Inter - GuruFocus
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):